NeuralBase Announces Beta Preview of BMP AI Workflow Prototype for Fintech Sector
This version already demonstrates early-stage capabilities in conversational automation, document-based reasoning, and AI-enhanced workflow support. The beta version is part of Neuralbase AI's phased development and feedback strategy focused on building high-trust, document-grounded AI systems for compliance-sensitive industries.
'This beta preview reflects our commitment to building enterprise AI that is secure, explainable, and fully grounded in verifiable documentation,' said Vighnesh Dobale, Chief Executive Officer of Neuralbase AI Ltd. 'While still under active development, this prototype provides an important starting point to gather feedback and validate key use cases within fintech operations.'
The current beta allows users to interact with a document-aware chatbot built using BMP AI's proprietary retrieval-augmented architecture, which enables grounded, traceable responses from internal source material. The Company plans to continue refining its interface, security controls, and enterprise integration features ahead of a broader rollout targeted for later this year.
This preview is being offered to select early partners, industry participants, and prospective clients for feedback purposes only. Interested parties are encouraged to contact the Company for access, feedback, or collaboration discussions.
Additional information about the Company is available at www.neuralbase.ai or by visiting www.sec.gov.
About NEURALBASE AI LTD.
NeuralBase AI Ltd. (OTC: NBBI) is an AI company developing secure, scalable, and context-aware conversational agents and workflow automation systems. Through its BMP AI platform - now in beta testing - the company enables organizations to streamline internal operations, enhance team collaboration, and increase productivity while maintaining strict compliance and data integrity.
Legal Disclaimer and Forward-Looking Statements
This press release contains forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, projections, and assumptions made by NeuralBase AI Ltd. (the 'Company' or 'NBBI') in light of experience, current conditions, anticipated future developments, and other factors. Forward-looking statements may include words such as 'aims,' 'anticipates,' 'believes,' 'plans,' 'expects,' 'intends,' 'will,' 'may,' 'could,' 'should,' and similar expressions.
These statements relate to, among other things, the expected performance and capabilities of the BMP AI platform; the Company's ability to successfully complete product development, enter commercial deployment, or scale its technology; future revenues and market expansion; and general strategic direction. All such statements are inherently uncertain and involve a number of risks that could cause actual results to differ materially from those expressed or implied in any forward-looking statement.
NeuralBase AI Ltd. is a fully reporting company with the U.S. Securities and Exchange Commission (SEC) and files annual and quarterly reports, current reports, and other required disclosures. All public filings and disclosures may be reviewed at the SEC's EDGAR database at www.sec.gov. The Company trades on the OTC Markets under the ticker symbol NBBI.
This press release is not, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of NeuralBase AI Ltd. in the United States or in any other jurisdiction. Offers and sales of securities, if any, will be made only pursuant to an effective registration statement or valid exemption under the U.S. Securities Act of 1933, as amended.
Investing in securities traded on the OTC Markets involves significant risk, including potential loss of principal, low liquidity, high volatility, and limited publicly available information. Shares traded on the OTC Markets may be more susceptible to market manipulation or price swings. Investors are strongly advised to conduct their own due diligence, consult a qualified investment advisor, and carefully review all SEC filings prior to making any investment decision.
Media Contact:
Vighnesh Dobale
Chief Executive Officer
[email protected]
(727) 314-3717
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
16 minutes ago
- Business Wire
Gold Reserve Wins Appeal at Portugal Supreme Court
PEMBROKE, Bermuda--(BUSINESS WIRE)--Gold Reserve Ltd. (TSX.V: GRZ) (OTCQX: GDRZF) ('Gold Reserve' or the 'Company') is pleased to announce that in a recently published decision, Portugal's Supreme Court upheld a decision recognizing the Company's 2014 international arbitration award (the 'Award') against the Bolivarian Republic of Venezuela ('Venezuela') and rejecting the state's sovereign immunity and public policy defenses. The total amount owed by Venezuela under the Award, inclusive of interest, exceeds $1.1 billion. In February 2025, the Lisbon Court of Appeal issued an order granting the Company's application to confirm the Award in Portugal and entered judgment for the Company against Venezuela in the amount of the Award. In the present decision, the Supreme Court of Justice affirmed the Court of Appeal's decision. Venezuela also was ordered to pay costs. A copy of the Supreme Court's decision can be found here. An English translation of the decision is being prepared and the Company's website. The Company's recognition and enforcement efforts in Portugal are in addition to those being undertaken in the United States, including the Company's being named on July 2, 2025 as the Final Recommended Bidder in the U.S. District Court for the District of Delaware for the sale of the shares of PDV Holdings, Inc. ('PDVH'), the indirect parent company of CITGO Petroleum Corp. Any satisfaction of the Company's judgment in the Delaware proceedings may set-off and reduce the amount that can be recovered on the Award in the Portugal legal proceedings, and vice-versa. Cautionary Statement Regarding Forward-Looking statements This release contains 'forward-looking statements' within the meaning of applicable U.S. federal securities laws and 'forward-looking information' within the meaning of applicable Canadian provincial and territorial securities laws and state Gold Reserve's and its management's intentions, hopes, beliefs, expectations or predictions for the future. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. They are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements contained in this press release include, but are not limited to, statements relating to any bid submitted by the Company for the purchase of the PDVH shares (the 'Bid'). We caution that such forward-looking statements involve known and unknown risks, uncertainties and other risks that may cause the actual events, outcomes or results of Gold Reserve to be materially different from our estimated outcomes, results, performance, or achievements expressed or implied by those forward-looking statements, including but not limited to recovery is not certain in the Portugal or Delaware legal proceedings due to multiple factors, including that, in Portugal, further court orders are required to attempt to collect against any of the attached funds, the priority of the Company's attachments on each account is not identical and is not definite, and the priority of the Company's attachments vis-à-vis other creditors is not identical and is not definite; and, in Delaware, the discretion of the Special Master to consider the Bid, to enter into any discussions or negotiation with respect thereto; the Bid will not be approved by the Court as the 'Final Recommend Bid' under the Bidding Procedures, and if approved by the Court may not close, including as a result of not obtaining necessary regulatory approvals, including but not limited to any necessary approvals from the U.S. Office of Foreign Asset Control ('OFAC'), the U.S. Committee on Foreign Investment in the United States, the U.S. Federal Trade Commission or the TSX Venture Exchange; failure of the Company or any other party to obtain sufficient equity and/or debt financing or any required shareholders approvals for, or satisfy other conditions to effect, any transaction resulting from the Bid; that the Company may forfeit any cash amount deposit made due to failing to complete the Bid or otherwise; that the making of the Bid or any transaction resulting therefrom may involve unexpected costs, liabilities or delays; that, prior to or as a result of the completion of any transaction contemplated by the Bid, the business of the Company may experience significant disruptions due to transaction related uncertainty, industry conditions, tariff wars or other factors; the ability to enforce the writ of attachment granted to the Company; the timing set for various reports and/or other matters with respect to the Sale Process may not be met; the ability of the Company to otherwise participate in the Sale Process (and related costs associated therewith); the amount, if any, of proceeds associated with the Sale Process; the competing claims of other creditors of Venezuela, PDVSA and the Company, including any interest on such creditors' judgements and any priority afforded thereto; uncertainties with respect to possible settlements between Venezuela and other creditors and the impact of any such settlements on the amount of funds that may be available under the Sale Process; and the proceeds from the Sale Process may not be sufficient to satisfy the amounts outstanding under the Company's September 2014 arbitral award and/or corresponding November 15, 2015 U.S. judgement in full; and the ramifications of bankruptcy with respect to the Sale Process and/or the Company's claims, including as a result of the priority of other claims. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements. For a more detailed discussion of the risk factors affecting the Company's business, see the Company's Management's Discussion & Analysis for the year ended December 31, 2024 and other reports that have been filed on SEDAR+ and are available under the Company's profile at Investors are cautioned not to put undue reliance on forward-looking statements. All subsequent written and oral forward-looking statements attributable to Gold Reserve or persons acting on its behalf are expressly qualified in their entirety by this notice. Gold Reserve disclaims any intent or obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of assumptions or factors, whether as a result of new information, future events or otherwise, subject to its disclosure obligations under applicable rules promulgated by applicable Canadian provincial and territorial securities laws.
Yahoo
23 minutes ago
- Yahoo
Avant Brands Announces Results for Q2 2025
KELOWNA, BC / / July 15, 2025 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BUP) ("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products, today released its financial results for the second quarter ended May 31, 2025 ("Q2 2025"). With a growing international footprint and deep penetration into key global medical markets, Avant continues to scale as the go-to Canadian exporter for top-shelf cannabis at commercial volume. The Company delivered its sixth consecutive quarter of positive Adjusted EBITDA1, supported by growth in Export Wholesale Revenue2 and disciplined operational execution. (1) Adjusted EBITDA is a non-GAAP performance measure. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at (2) Export Wholesale Revenue is a non-GAAP performance measure. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at Highlights include: Gross and Net Revenue Increases: Gross Revenue increased 3% to $9.7 million, while Net Revenue increased 3% to $8.5 million as compared to Q2 2024, driven by sustained international demand for premium cannabis and strong relationships with customers. Export Wholesale Revenue2: Export Wholesale Revenue2 reached $4.1 million, representing an 11% increase over Q2 2024, reflecting Avant's expanding presence in key international medical markets such as Germany, Israel, and Australia. (2) Export Wholesale Revenue is a non-GAAP performance measure. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at Domestic Wholesale Revenue3: Domestic Wholesale Revenue3 reached $1.3 million, representing a 31% increase over Q2 2024. (3) Domestic Wholesale Revenue is a non-GAAP performance measure. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at Adjusted EBITDA1: Achieved Adjusted EBITDA1 of $1.2 million, marking the sixth consecutive quarter of positive Adjusted EBITDA1. (1) Adjusted EBITDA is a non-GAAP performance measure. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at Net Cash Flows Generated from Operating Activities: Net cash flows generated from operating activities year to date ("YTD") increased 7% to $2.6 million as compared to Q2 2024. Avant Brands Founder & CEO Norton Singhavon Comments: "Avant is executing at a global scale. We are establishing ourselves as the leading Canadian exporter of high-grade cannabis, trusted by top-tier distributors in markets like Germany, Israel, and Australia. Our ability to deliver consistent, premium-quality product at scale is what sets us apart. As international demand accelerates, our focus remains on building globally recognized brands and solidifying Avant's position as the standard for Canadian cannabis on the world stage." Fiscal Q2 2025 Financial Highlights (vs. Fiscal Q2 2024): Revenue: Gross Revenue: $9.7 million (+3%) Net Revenue: $8.5 million (+3%) Export Wholesale Revenue2: $4.1 million (+11%) Recreational Revenue4: $2.9 million (-14%) Domestic Wholesale Revenue3: $1.3 million (+37%) (2) Export Wholesale Revenue is a non-GAAP performance measure. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at (3) Domestic Wholesale Revenue is a non-GAAP performance measure. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at (4) Recreational Revenue is a non-GAAP performance measure. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at Recreational Revenue4 declined because of a strategic shift toward higher-margin, top-performing SKUs. This realignment is expected to drive long-term profitability, while resources continue to be prioritized toward scaling international operations. (4) Recreational Revenue is a non-GAAP performance measure. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at Gross Margin adjusted for fair value adjustments5: Gross Margin adjusted for fair value adjustments5: Decreased to $2.2 million (-27%) due to improved Cost of Sales allocations. Gross Margin % adjusted for fair value adjustments6: Decreased to 26% (vs. 37%). YTD Net Cash Flows Generated from Operating activities increased 7% versus the comparative period, inclusive of the improved allocations to Cost of Sales. (5) Gross Margin adjusted for fair value adjustments is a non-GAAP performance measure. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at (6) Gross Margin % adjusted for fair value adjustments is a non-GAAP performance ratio. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at Adjusted EBITDA1 Achieved Adjusted EBITDA1 of $1.2 million, marking the sixth consecutive quarter of positive Adjusted EBITDA1. (1) Adjusted EBITDA is a non-GAAP performance measure. The information is incorporated by reference from the Q2 2025 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at Cannabis Production and Sales: Cannabis Production: 3,327 KG (+4%). Cannabis Sales: 2,799 KG sold (+3%). About Avant Brands Inc. Avant Brands Inc. (TSX: AVNT) (OTCQX: AVTBF) (FRA: 1BUP) is a leading innovator in premium cannabis products, driven by a commitment to exceptional quality and craftsmanship. As one of Canada's largest indoor producers, the company operates multiple production facilities across the country, cultivating unique and high-quality cannabis strains. Avant offers a diverse product portfolio catering to recreational, medical, and export markets. Its renowned consumer brands, including blk mkt™, Tenzo™, Cognōscente™, flowr™, and Treehugger™, are available in key recreational markets across Canada. The company's international footprint spans Australia, Israel, and Germany, with its flagship brand blk mkt™ leading the way. Avant also serves qualified medical patients nationwide through its GreenTec™ medical cannabis brand, accessible via the GreenTec Medical portal and trusted partner network. Avant is a publicly traded company, listed on the Toronto Stock Exchange (TSX) and accessible to international investors through the OTCQX Best Market (OTCQX) and Frankfurt Stock Exchange (FRA). Headquartered in Kelowna, British Columbia, the company operates in strategic locations throughout Canada. Learn More:For more information about Avant, including investor presentations and details about its consumer brands, please visit the company website: Investor Relations:For inquiries, please contact Avant Brands Investor Relations at 1-800-351-6358 or ir@ CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking information" as defined under applicable Canadian securities legislation, encompassing statements regarding Avant Brands Inc.'s ("Avant" or the "Company") plans, intentions, beliefs, and current expectations concerning future business activities and operating performance. Forward-looking information is often, but not always, identified by the use of words such as "expects," "intends," "anticipates," "believes," "estimates," "plans," "may," "could," "should," "will," or variations of such words and phrases. In particular, this news release includes forward-looking information related to, but not limited to, the Company's expectations for future revenue and sales growth, the continued performance of its international operations, the demand for its premium cannabis products-including the blk mkt™ brand-in key global markets, and the Company's strategic initiatives to prioritize high-performing SKUs, streamline its domestic offerings, and expand its presence in Australia, Germany, Israel, and other international jurisdictions. Forward-looking information also includes statements concerning the Company's ongoing focus on operational efficiencies, profitability, and the anticipated availability of financial statements and management's discussion and analysis ("MD&A") on the Company's SEDAR+ profile and website, providing investors with comprehensive financial information. Investors should be aware that forward-looking information involves inherent risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such information. Management's current expectations may not accurately predict future events or outcomes. Therefore, investors are cautioned not to place undue reliance on forward-looking information. Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management's expectations, estimates, or projections concerning future results or events based on the opinions, assumptions, and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; changes in consumer demand and preferences; changes in general economic, business, and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in the Company's annual information form dated February 28, 2025 filed with Canadian securities regulators and available on the Company's profile on SEDAR+ at Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties, and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated, or intended. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date of this news release. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by law. SPECIAL NOTE REGARDING FINANCIAL INFORMATION This document should be read in conjunction with the Company's unaudited interim consolidated financial statements (the "financial statements") and the Company's MD&A for the three months and six months ended May 31, 2025, and audited consolidated financial statements for the year ended November 30, 2024. All dollar amounts are referenced in millions of Canadian dollars, except where noted otherwise. The Company's financial statements and MD&A for the three months and six months ended May 31, 2025 have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). Additional information relating to the Company, including its Annual Information Form for the year ended November 30, 2024, is available on SEDAR+ at Information on the Company's website does not form part of and is not incorporated by reference in the Company's MD&A. SPECIAL NOTE REGARDING NON-GAAP AND OTHER FINANCIAL MEASURES This document includes references to non-GAAP measures, which include non-GAAP and other financial measures as defined in National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure. These financial measures are used by the Company to evaluate its financial performance, financial position or cash flow and include non-GAAP financial measures, non-GAAP ratios, total of segments measures, capital management measures, and supplementary financial measures. These financial measures are not defined by IFRS and therefore are referred to as non-GAAP and other financial measures. The non-GAAP and other financial measures used by the Company may not be comparable to similar measures presented by other companies, and should not be considered an alternative to or more meaningful than the most directly comparable financial measure presented in the Company's financial statements, as applicable, as an indication of the Company's performance. Descriptions of the Company's non-GAAP and other financial measures included in this document, and reconciliations to the most directly comparable GAAP measure, as applicable, are provided in the "Cautionary Statement Regarding Certain Non-Gaap Performance Measures" section of the Company's MD&A for the three months and six months ended May 31, 2025, dated July 15th, 2025. SOURCE: Avant Brands Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
32 minutes ago
- Business Wire
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the 'Company'), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2025. Financial Results The revenues for the second quarter of fiscal 2025 were $7.9 million compared to $8.0 million for the second quarter of fiscal 2024, a 1% decrease. The revenues for the second quarter of fiscal 2025 consisted of $7.87 million in processing and storage fee revenue, $43,000 in public banking revenue and $14,000 in product revenue compared to $7.97 million in processing and storage fee revenue, $41,000 in public banking revenue and $36,000 in product revenue for the second quarter of fiscal 2024. Net Income The Company reported net income of $356,000, or $0.04 per basic and diluted common shares for the three months ended May 31, 2025, compared to net income of $656,000, or $0.08 per basic and diluted common shares for the three months ended May 31, 2024. About Cryo-Cell International, Inc. Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby's cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell International has a public banking program in partnership with Duke University. Cryo-Cell's public bank has provided cord blood for more than 700 transplants and operates cord blood donation sites in prominent hospitals such as Cedars–Sinai Hospital in Los Angeles. Cryo-Cell's facility is FDA registered, cGMP-/cGTP-compliant and licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. Cryo-Cell has the exclusive rights to PrepaCyte-CB, the industry's most advanced cord blood processing technology. Cryo-Cell's mission is to provide premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available. In February 2021, Cryo-Cell entered into a license agreement with Duke University that the Company believes has allowed Cryo-Cell to begin its transformation into an autonomous, vertically integrated cellular therapy company. In March 2022, Cryo-Cell launched ExtraVault to offer its expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions. For more information, please visit Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). In some cases, you can identify forward-looking statements by terminology such as 'will,' 'may,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'predicts,' 'forecasts,' 'potential' or 'continue' or the negative of these terms or other comparable terminology. Generally, the words 'anticipate,' 'believe,' 'continue,' 'expect,' 'intend,' 'estimate,' 'project,' 'plan' and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, the success of the Company's global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company's actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company's future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company's business, the success of the Company's initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the complexities, uncertainties, required consents and timing related to the potential spinoff of Celle Corp., the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company's ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company's umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, along with the Risk Factors set forth in the Company's Form 10-Q filed on July 15, 2025. This list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements.
